Trusted Resource for Clinical Trials, Protocols & Progress
Traditional clinical development often faces delays due to the high rate of failures in early-stage trials. Phase 0 studies emerged as a response, offering a faster and cost-effective means of assessing drug behavior in humans. These trials use microdoses that are far below therapeutic levels, ensuring minimal risk while providing valuable data to guide subsequent clinical phases.
Click to read the full article.
Phase 0 trials, also known as microdosing studies, are the earliest phase of human clinical research. Introduced as part of an exploratory IND (Investigational New Drug) framework by the U.S. FDA, Phase 0 studies are designed to collect preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data in humans using very low doses of investigational drugs.
Click to read the full article.
A microdosing study involves the administration of extremely low, sub-therapeutic doses of a drug to human subjects to evaluate early pharmacokinetic (PK) and pharmacodynamic (PD) behavior. These studies fall under the category of Phase 0 clinical trials and are designed to provide rapid, human-specific data with minimal risk.
Click to read the full article.
Even though Phase 0 trials involve microdoses and no therapeutic intent, they are still clinical trials involving human participants. This means they must adhere to the highest ethical and safety standards. The fact that Phase 0 studies may offer no direct benefit to the subject makes ethical oversight even more critical.
Click to read the full article.
Phase 0 trials, although short and low-risk, are still governed by regulatory frameworks. Before starting human studies, sponsors must obtain authorization from national health authorities. This ensures that human subjects are protected and the study is scientifically and ethically justified.
Click to read the full article.
Phase 0 trials provide early human pharmacokinetic and target engagement data. Phase 1 trials explore safety and dose tolerance. Combining these phases into a seamless development strategy using adaptive trial designs offers speed, efficiency, and data continuity. This approach is especially valuable for high-risk, high-reward programs such as oncology, CNS, or rare disease pipelines.
Click to read the full article.
